COMT Inhibitors

DBCAT002655Therapeutic category

Compounds and drugs that inhibit or block the activity of CATECHOL O-METHYLTRANSFERASE enzymes. Drugs in this class are used in management of central nervous system disorders such as PARKINSON DISEASE. A DrugBank category of 12 drugs. 4 of them are approved.

Also known as: Catechol O Methyltransferase Inhibitors · Catechol O-Methyltransferase Inhibitors · Catechol-o-methyltransferase (Comt) Inhibitors · Catechol-O-Methyltransferase Inhibitor · COMT-Inhibitors
Drugs: (3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE
3,5-Dinitrocatechol
7,8-dihydroxy-4-phenyl-2H-chromen-2-one
BIA
Entacapone
Nebicapone
Nitecapone
Opicapone
Phloroglucinol
Quercetin
Testosterone propionate
Tolcapone

What you can answer from here — as of August 12, 2019

12DrugsEach linked to its full drug card

Listed above

39Drug targetsEvery drug–target pair in the class, with bond type

959Marketed productsAcross the regions we cover, with dosage forms and routes

6Routes of administrationHow the drugs in this class are given

Which targets do COMT Inhibitors share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account